Suppr超能文献

世界反兴奋剂机构禁用物质综述:对提高运动表现效果的有限证据。

Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects.

机构信息

Centre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The Netherlands.

Department of Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands.

出版信息

Sports Med. 2019 Apr;49(4):525-539. doi: 10.1007/s40279-018-1014-1.

Abstract

The World Anti-Doping Agency is responsible for maintaining a Prohibited List that describes the use of substances and methods that are prohibited for athletes. The list currently contains 23 substance classes, and an important reason for the existence of this list is to prevent unfair competition due to pharmacologically enhanced performance. The aim of this review was to give an overview of the available evidence for performance enhancement of these substance classes. We searched the scientific literature through PubMed for studies and reviews evaluating the effects of substance classes on performance. Findings from double-blind, randomized controlled trials were considered as evidence for (the absence of) effects if they were performed in trained subjects measuring relevant performance outcomes. Only 5 of 23 substance classes show evidence of having the ability to enhance actual sports performance, i.e. anabolic agents, β2-agonists, stimulants, glucocorticoids and β-blockers. One additional class, growth hormone, has similar evidence but only in untrained subjects. The observed effects all relate to strength or sprint performance (and accuracy for β-blockers); there are no studies showing positive effects on reliable markers of endurance performance. For 11 classes, no well-designed studies are available, and, for the remaining six classes, there is evidence of an absence of a positive effect. In conclusion, for the majority of substance classes, no convincing evidence for performance enhancement is available, while, for the remaining classes, the evidence is based on a total of only 266 subjects from 11 studies.

摘要

世界反兴奋剂机构负责维护一份禁用清单,其中描述了禁止运动员使用的物质和方法。该清单目前包含 23 个物质类别,存在该清单的一个重要原因是防止因药物增强表现而导致的不公平竞争。本综述旨在概述这些物质类别对表现的增强作用的现有证据。我们通过 PubMed 搜索了评估物质类别对表现影响的研究和综述。如果在接受过训练的、测量相关表现结果的受试者中进行了双盲、随机对照试验,那么这些试验的结果被认为是有(无)效果的证据。在 23 个物质类别中,仅有 5 个具有增强实际运动表现的能力,即合成代谢剂、β2-激动剂、兴奋剂、糖皮质激素和β-阻断剂。另外一类生长激素也有类似的证据,但仅在未经训练的受试者中。观察到的效果都与力量或短跑表现(β-阻断剂的准确性)有关;没有研究表明对耐力表现的可靠标志物有积极影响。对于 11 个类别,没有设计良好的研究可用,而对于其余的 6 个类别,有证据表明没有积极的效果。总之,对于大多数物质类别,没有令人信服的表现增强证据,而对于其余的类别,证据仅基于总共来自 11 项研究的 266 名受试者。

相似文献

1
Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects.
Sports Med. 2019 Apr;49(4):525-539. doi: 10.1007/s40279-018-1014-1.
2
Investigating the use of stimulants in out-of-competition sport samples.
J Anal Toxicol. 2011 Nov;35(9):613-6. doi: 10.1093/anatox/35.9.613.
4
Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 15;927:22-36. doi: 10.1016/j.jchromb.2012.12.003. Epub 2012 Dec 20.
5
Analytical strategy for detecting doping agents in hair.
Forensic Sci Int. 2000 Jan 10;107(1-3):335-45. doi: 10.1016/s0379-0738(99)00177-2.
6
Structure and Development of the List of Prohibited Substances and Methods.
Med Sport Sci. 2017;62:39-54. doi: 10.1159/000460699. Epub 2017 Jun 1.
7
Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.
Fundam Clin Pharmacol. 2011 Oct;25(5):535-63. doi: 10.1111/j.1472-8206.2010.00881.x. Epub 2010 Oct 6.
8
Australian athletes' knowledge of the WADA Prohibited Substances List and performance enhancing substances.
Int J Drug Policy. 2018 Jun;56:40-45. doi: 10.1016/j.drugpo.2018.02.025. Epub 2018 Mar 15.
9
Annual banned-substance review: analytical approaches in human sports drug testing.
Drug Test Anal. 2016 Jan;8(1):7-29. doi: 10.1002/dta.1928. Epub 2016 Jan 15.
10
Annual banned-substance review: analytical approaches in human sports drug testing.
Drug Test Anal. 2015 Jan;7(1):1-20. doi: 10.1002/dta.1769. Epub 2014 Dec 26.

引用本文的文献

4
A cross-sectional study on metoprolol concentrations in various biological samples and their inter-correlations.
BMC Pharmacol Toxicol. 2024 Aug 8;25(1):45. doi: 10.1186/s40360-024-00773-3.
5
Exploring the scope and applications of anti-doping measures in ultramarathon: an analysis of the positions of ultramarathon race organizers.
Front Sports Act Living. 2024 May 22;6:1406638. doi: 10.3389/fspor.2024.1406638. eCollection 2024.
6
Development of an Ephedrine In-House Matrix Reference Material and Its Application to Doping Analysis.
ACS Omega. 2024 Mar 8;9(11):12689-12697. doi: 10.1021/acsomega.3c08316. eCollection 2024 Mar 19.
7
Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations.
Cureus. 2024 Jan 10;16(1):e52011. doi: 10.7759/cureus.52011. eCollection 2024 Jan.
8
Performance-Enhancing Drugs in Healthy Athletes: An Umbrella Review of Systematic Reviews and Meta-analyses.
Sports Health. 2024 Sep-Oct;16(5):695-705. doi: 10.1177/19417381231197389. Epub 2023 Sep 9.
9
The molecular athlete: exercise physiology from mechanisms to medals.
Physiol Rev. 2023 Jul 1;103(3):1693-1787. doi: 10.1152/physrev.00017.2022. Epub 2023 Jan 5.
10
Trimetazidine Blocks Lipid Oxidation-Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis?
J Diabetes Sci Technol. 2022 Sep;16(5):1063-1068. doi: 10.1177/19322968221100196. Epub 2022 Jun 2.

本文引用的文献

3
Analgesics and Sport Performance: Beyond the Pain-Modulating Effects.
PM R. 2018 Jan;10(1):72-82. doi: 10.1016/j.pmrj.2017.07.068. Epub 2017 Aug 4.
4
Marijuana and Its Effects on Athletic Performance: A Systematic Review.
Clin J Sport Med. 2018 Jul;28(4):350-357. doi: 10.1097/JSM.0000000000000471.
5
Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial.
Lancet Haematol. 2017 Aug;4(8):e374-e386. doi: 10.1016/S2352-3026(17)30105-9. Epub 2017 Jun 29.
6
Cannabis: Exercise performance and sport. A systematic review.
J Sci Med Sport. 2017 Sep;20(9):825-829. doi: 10.1016/j.jsams.2017.03.012. Epub 2017 Mar 21.
7
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Am J Kidney Dis. 2017 Jun;69(6):815-826. doi: 10.1053/j.ajkd.2016.12.011. Epub 2017 Feb 24.
8
Temporal changes in physiology and haematology in response to high- and micro-doses of recombinant human erythropoietin.
Drug Test Anal. 2017 Oct;9(10):1561-1571. doi: 10.1002/dta.2176. Epub 2017 Apr 11.
9
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.
Am J Nephrol. 2017;45(3):187-199. doi: 10.1159/000455166. Epub 2017 Jan 25.
10
Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
Expert Opin Ther Targets. 2017 Mar;21(3):333-348. doi: 10.1080/14728222.2017.1280467. Epub 2017 Jan 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验